Chk inhibitors can hinder the self-repair of tumor cells, thereby achieving the goal of enhancing the killing of tumor cells.

SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.

BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).

Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.

This article summarized the latest R&D progress of Vosoritide, the Mechanism of Action for Vosoritide, and the drug target R&D trends for Vosoritide.

Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.

The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.

NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.

This article summarized the latest R&D progress of Vincamine, the Mechanism of Action for Vincamine, and the drug target R&D trends for Vincamine.

Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.

The latest clinical findings of Ianalumab were unveiled at the 2023 AACR Congress, demonstrating its potential effect and setting the stage for subsequent investigations.

Ionis Pharmaceuticals reported successful recruitment completion and encouraging early outcomes from the first phase of the HALOS Phase 1/2a trial for ION582 (BIIB121) targeting Angelman syndrome.